Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection

Journal of Hepatology

Volumn 66, Issue 1, 2017, Pages 242-243

  van der Valk, Marc ^a   Zaaijer, Hans L ^b   Kater, Arnon P ^b   Schinkel, Janke ^b  

^a Center for Infection and Immunity Amsterdam CINIMA   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RIBAVIRIN; RITUXIMAB; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CASE REPORT; CHRONIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; GENE MUTATION; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA RELAPSE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT DURATION; VIRAL CLEARANCE; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECT; GENETICS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS E; HEPATITIS E VIRUS; HEPATITIS, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR;

EID: 85005769258     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.09.014     Document Type: Letter

References (5)

1. [1] Kamar, N., Bendall, R., Legrand-Abravanel, F., Xia, N.S., Ijaz, S., Izopet, J., et al. Hepatitis E. Lancet 379 (2012), 2477–2488.
2. [2] Peters van Ton, A.M., Gevers, T.J., Drenth, J.P., Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 22 (2015), 965–973.
3. [3] Dao Thi, V.L., Debing, Y., Wu, X., Rice, C.M., Neyts, J., Moradpour, D., et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 150 (2016), 82–85, e4.
4. [4] Sofia, M.J., Bao, D., Chang, W., Du, J., Nagarathnam, D., Rachakonda, S., et al. Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53 (2010), 7202–7218.
5. [5] Todt, D., Gisa, A., Radonic, A., Nitsche, A., Behrendt, P., Suneetha, P.V., et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 65 (2016), 1733–1743.